|
SkinBioTherapeutics on Monday confirmed the appointment of Interim Chief Executive Officer Rachel Parsonage to its board after completing regulatory due diligence. Parsonage was appointed as interim CEO of the Newcastle Upon Tyne, England-based life sciences firm last week but her place on the board was subject to normal regulatory due diligence by the firm’s adviser. In addition to this role, she is currently running her own advisory consultancy firm, Alera Advisory, and held various managerial positions at KMI Brands for 16 years. Her appointment was triggered by the sudden departure of the company’s former CEO in February, coupled with the start of an investigation by the board over reported accrued royalty income. The news caused the share price to sink over 70% in days, trading from around 20p a share to lows of 5p. SkinBio shares partially recovered since February’s crash but are still down 29% in the year to date. SkinBio shares were down 5.3% to 11.84 pence each on Monday afternoon in London. Executive Chair Martin Hunt said: ‘Rachel has been in the post of interim CEO for just a week so far, and already, she has met the majority of the team and is getting under the skin of the business, including building relationships with our key partners. Her deep experience in leading consumer beauty and wellness companies is evident in her approach, and she has a clear plan of what she wants to achieve in the immediate near term. In the meantime, we are waiting for the outcome of the external investigation as well as preparing for the half-year results.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
